MEK Inhibitors

Mechanism

Related News

Nurix Highlights Oncology and Immunology Degrader Pipeline Progress

May 18, 2026

Nurix reported new oncology preclinical data at AACR 2026 and outlined progress in its immunology degrader pipeline. The company said NX-3911 could enter an IND this year and Phase 1 data for bexobrutideg are planned this year.

FAERS analysis flags 13 systemic medications with high uveitis reporting signals

Apr 11, 2026

A FAERS database analysis identified 13 FDA-approved systemic medications with disproportionately high uveitis reporting signals among 7,301 events from 2003 to 2024. The strongest signals were for cidofovir and rifabutin, and the findings were described as hypothesis-generating rather than causal.